Two new directors join company’s board
MADISON, Wis., Nov. 30, 2006—Renovar Inc., an early-stage company focused on the development of kidney disease diagnostics, today announced that it has closed a successful round of financing that totals $1.22 million.  This financing round, Renovar’s second, brings the total capital raised by the company to $3.2 million.  The proceeds will be used to support the company’s efforts to secure FDA clearance of its Renokine I product, and other product research and development activities.